Dr. David J. Mcdonald, MD
Neurology (Diagnostic Neuroimaging (Psychiatry & Neurology) Physician)
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 639
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Tufts University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Diagnostic Neuroimaging (Psychiatry & Neurology) Physician primary
FL license ME070742 -
Specialist
FL license ME0070742
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Daytona Beach Daytona Beach, FL
- Halifax Health Medical Center Daytona Beach, FL
- Halifax Health /uf Health Medical Center of Delton Deltona, FL
Medical groups
- Halifax Healthcare Systems Inc (356 clinicians)
- Neurology Associates of Ormond Beach PA (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 639
- Services billed
- 1,978
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 6,668 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 469 | 153 |
| Established patient office or other outpatient visit, 20-29 minutes | 208 | 167 |
| Measurement of brain wave activity (eeg), awake and asleep | 189 | 170 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 186 | 88 |
| Established patient office or other outpatient visit, 30-39 minutes | 134 | 114 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 128 | 124 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 52 | 23 |
| Mri scan of brain before and after contrast | 48 | 46 |
| New patient office or other outpatient visit, 60-74 minutes | 47 | 47 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 75 payments worth $1,744 in total to this clinician.
| AbbVie Inc. | $263 |
|---|---|
| Pfizer Inc. | $150 |
| UCB, Inc. | $133 |
| Novartis Pharmaceuticals Corporation | $121 |
| Sk Life Science, Inc. | $92.93 |
| Eisai Inc. | $84.75 |
| Lilly USA, LLC | $84.13 |
| Amgen Inc. | $80.13 |
| Food and Beverage | $1,744 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $216,725 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
AbbVie Inc. · Completed · NCT05291234 - M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease
AbbVie Inc. - A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.